Adexsolhttp://adexsol.com/
ADEXSOL vous apporte son expertise du système de santé et du marché des produits de santé en France à travers ses quatre activités : conseil , formation, communication, études.frSPIP - www.spip.netAbout Alexis Dussol, Founder and CEO of ADEXSOLhttp://adexsol.com/About-Alexis-Dussol-Founder-and
http://adexsol.com/About-Alexis-Dussol-Founder-and2013-11-29T08:08:58Ztext/htmlenAlexis<p>Alexis Dussol has held several management positions within the public sector and healthcare communication agencies, <strong>making him one of the best experts of the healthcare system and market.</strong></p>
-
<a href="http://adexsol.com/-Who-are-we-" rel="directory">Who are we?</a>
<img class='spip_logos' alt="" align="right" src="http://adexsol.com/IMG/arton25.png" width='150' height='114' />
<div class='rss_texte'><p>Graduating from the Ecole des Hautes Etudes de Sante Publique, <strong>Alexis Dussol has been the managing director of several French hospitals.</strong> He also managed the event and training department of Decision Santé.</p> <p>He was the <strong>president of the national conference of hospitals directors from 1997 to 2003</strong> and has also been a board member of the National Health Conference Bureau.</p> <p>He is the author of a book about generic medication (Que Sais-Je? Le medicament generique)</p> <p>He also collaborates on a regular basis with specialist magazines, moderates events and sets up training about healthcare current affairs.</p> <p>From his professional experience, <strong>Alexis Dussol has become one of the rare experts to have a double competence in healthcare management and communication.</strong></p></div>
Robotic Surgery - Key Figureshttp://adexsol.com/Robotic-Surgery-Key-Figures-45
http://adexsol.com/Robotic-Surgery-Key-Figures-452013-11-27T11:57:38Ztext/htmlfrAlexisMedicine Technology
-
<a href="http://adexsol.com/-Key-Figures-" rel="directory">Library</a>
/
<a href="http://adexsol.com/+-Medicine-+" rel="tag">Medicine </a>,
<a href="http://adexsol.com/+-Technology-+" rel="tag">Technology </a>
Janssen/ Deloitte - Investing in European health R&Dhttp://adexsol.com/Investing-in-European-health-R-D
http://adexsol.com/Investing-in-European-health-R-D2013-10-15T19:59:07Ztext/htmlfrAlexis
-
<a href="http://adexsol.com/-Key-Figures-" rel="directory">Library</a>
European Health R&D hit by the crisishttp://adexsol.com/European-Health-R-D-hit-by-the
http://adexsol.com/European-Health-R-D-hit-by-the2013-10-09T19:06:27Ztext/htmlenAlexisPolitics Research
<p>For the first time in history, health R&D investments stagnate in Europe since 2010, after decades of increase, reports Deloitte on behalf of Janssen.<br class='autobr' />
To put this in perspective, 60% of the 47 billion euros invested in 2011 were by the pharmaceutical industry and 40% by member states - this amount being 3% of EU total healthcare expenditure.<br class='autobr' />
Private investments have stagnated for the first time, while public investments decreased by 1% - US investment decreased even more sharply, but (...)</p>
-
<a href="http://adexsol.com/-Latest-News-" rel="directory">Latest News</a>
/
<a href="http://adexsol.com/+-Politics-+" rel="tag">Politics </a>,
<a href="http://adexsol.com/+-Research-+" rel="tag">Research </a>
<img class='spip_logos' alt="" align="right" src="http://adexsol.com/IMG/arton29.png" width='150' height='80' />
<div class='rss_texte'><p>For the first time in history, health R&D investments stagnate in Europe since 2010, after decades of increase, reports Deloitte on behalf of Janssen.</p> <p>To put this in perspective, 60% of the 47 billion euros invested in 2011 were by the pharmaceutical industry and 40% by member states - this amount being 3% of EU total healthcare expenditure.</p> <p>Private investments have stagnated for the first time, while public investments decreased by 1% - US investment decreased even more sharply, but remains twice as high as in Europe (91 billion, of which 53% are private investments).</p> <p>Within Europe, the major investor in healthcare R&D is Germany (9.4 million) followed by France (8.3 million) then the UK (7.4 million).</p> <p>This reports shows that the decline is evidently due to the economic situation but also to limited reward mechanisms for innovative technologies.</p> <p>In the context of ageing populations and increasing chronic pathologies, this situation appears undesirable - preventing millions of people having improved health.</p></div>
Who are we ?http://adexsol.com/Who-are-we-24
http://adexsol.com/Who-are-we-242013-09-30T09:32:42Ztext/htmlenAlexis<p>ADEXSOL is a consulting and training company based in Paris that provides <strong>healthcare companies and institutions with knowledge of the goals, organisation and functioning of the French healthcare system.<br class='autobr' />
</strong></p>
-
<a href="http://adexsol.com/-Who-are-we-" rel="directory">Who are we?</a>
<img class='spip_logos' alt="" align="right" src="http://adexsol.com/IMG/arton24.png" width='150' height='100' />
<div class='rss_texte'><p>ADEXSOL can help you with:</p> <p><img src="http://adexsol.com/local/cache-vignettes/L16xH14/puce-32883.gif" width='16' height='14' class='puce' alt="-" /> Better <strong>understanding and analysing needs of the hospital and healthcare world</strong> in order to build an offer meeting key players' needs.</p> <p><img src="http://adexsol.com/local/cache-vignettes/L16xH14/puce-32883.gif" width='16' height='14' class='puce' alt="-" /> Setting up training for industry<strong> sales forces and managers</strong> on topics related to <strong>organisation and functioning of the hospital.</strong></p> <p><img src="http://adexsol.com/local/cache-vignettes/L16xH14/puce-32883.gif" width='16' height='14' class='puce' alt="-" /> Carrying out <strong>market research, polls and opinion trackers.</strong></p> <p><img src="http://adexsol.com/local/cache-vignettes/L16xH14/puce-32883.gif" width='16' height='14' class='puce' alt="-" /> <strong>Organising events</strong> nationally or regionally: conferences, workshops, seminars, and scientific boards.</p> <p><img src="http://adexsol.com/local/cache-vignettes/L16xH14/puce-32883.gif" width='16' height='14' class='puce' alt="-" /> Developing your <strong>Market Access strategies.</strong></p> <p>We have a <strong>wide network of stakeholders</strong> (parliamentarian, elected representatives, clinic and hospital directors, presidents of drug committees, unions leaders, associations, etc.)</p> <p>We also benefit from <strong>partnerships</strong> with <strong>communication agencies, newspapers and other services</strong> allowing us to <strong>offer global solutions while still being close to your needs.</strong></p> <p>ADEXSOL is also<strong> based in London</strong> and therefore can help English speaking companies in their development in the French market.</p> <p>In a healthcare context continuously affected by major changes, ADEXSOL can provide you with <strong>its expertise and knowledge of stakeholders and their needs, with high levels of quality and ethic.</strong></p> <p><strong>Listening, responsiveness and broad expertise are our strengths.</strong></p></div>
The New Industrial Francehttp://adexsol.com/The-New-Industrial-France
http://adexsol.com/The-New-Industrial-France2013-09-12T16:24:00Ztext/htmlenAlexisPolitics Technology
<p>“Medical biotechnologies”, “Digital hospital”, and “New Medical Devices” appear among the 34 plans of “industrial recovery” presented by the French president on the 12th of September at Elysée Palace.<br class='autobr' />
McKinsey estimated the potential of these 34 plans to be 480,000 jobs in 10 years and 45.5 billion Euros of generated value – 40% of which for exportation.<br class='autobr' />
The plan “Medical Biotechnologies” will allow the reinforcement of France's position in terms of synthetic biotechnology and cell therapy by (...)</p>
-
<a href="http://adexsol.com/-Latest-News-" rel="directory">Latest News</a>
/
<a href="http://adexsol.com/+-Politics-+" rel="tag">Politics </a>,
<a href="http://adexsol.com/+-Technology-+" rel="tag">Technology </a>
<img class='spip_logos' alt="" align="right" src="http://adexsol.com/IMG/arton31.png" width='150' height='101' />
<div class='rss_texte'><p>“Medical biotechnologies”, “Digital hospital”, and “New Medical Devices” appear among the 34 plans of “industrial recovery” presented by the French president on the 12th of September at Elysée Palace.</p> <p>McKinsey estimated the potential of these 34 plans to be 480,000 jobs in 10 years and 45.5 billion Euros of generated value – 40% of which for exportation.</p> <p>The plan “Medical Biotechnologies” will allow the reinforcement of France's position in terms of synthetic biotechnology and cell therapy by consolidating partnership research and supporting biotechnology companies' development and offer.</p> <p>The plan “Digital Hospital” will also allow the government to increase healthcare quality, to control spending and to offer growth opportunities to the French industrial force.</p> <p>In the medical devices area, the French government's ambition is to position its industrial offer on high added value segments such as imagery (scanner, ultrasound, endoscopy) or e-health (telecardiology, management and analysis of patient data).</p></div>
Test menu2http://adexsol.com/Test-menu2
http://adexsol.com/Test-menu22013-08-01T14:52:42Ztext/htmlfrAlexis
-
<a href="http://adexsol.com/-Home-" rel="directory">Home</a>